Medical Devices

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

For patients with slow-growing lymphoma, "watch-and-wait" can be agonizing. A novel immunotherapy is showing promise in replacing anxiety with action.

Imviva Biotech's 'off-the-shelf' cell therapies could make life-saving treatments faster and more accessible. But what does this mean for patients?

FDA clears Phase IIb trial for CS1, an epigenetic drug aiming to reverse PAH damage, not just manage symptoms, signaling a major market and patient shift.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

Vapotherm partners with Flight Medical, launching the VentO2ux ventilator to challenge market giants and redefine emergency respiratory care in the US.

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.

With a new SVP of Growth, John Henry, RestorixHealth signals an aggressive push in the booming wound care market, navigating tech shifts and regulatory hurdles.

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.

A South Korean biotech's novel antibody, now named rapaprutug, could shift the paradigm for pulmonary arterial hypertension by targeting its root causes.

SS Innovations is betting its cost-efficient SSi Mantra robot can break into the U.S. market. Will affordability democratize the operating room?

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

A new clinical trial in Malaysia could democratize advanced cancer care, testing an affordable, donor-derived immunotherapy challenging costly personalized treatments.

Fate Therapeutics' latest data suggests its iPSC-derived CAR-T could revolutionize lupus care, moving cell therapy beyond cancer and into the mainstream.